237 related articles for article (PubMed ID: 23175357)
1. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.
Alam SM; Liao HX; Tomaras GD; Bonsignori M; Tsao CY; Hwang KK; Chen H; Lloyd KE; Bowman C; Sutherland L; Jeffries TL; Kozink DM; Stewart S; Anasti K; Jaeger FH; Parks R; Yates NL; Overman RG; Sinangil F; Berman PW; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Karasavva N; Rerks-Ngarm S; Kim JH; Michael NL; Zolla-Pazner S; Santra S; Letvin NL; Harrison SC; Haynes BF
J Virol; 2013 Feb; 87(3):1554-68. PubMed ID: 23175357
[TBL] [Abstract][Full Text] [Related]
2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
4. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.
Morales JF; Morin TJ; Yu B; Tatsuno GP; O'Rourke SM; Theolis R; Mesa KA; Berman PW
J Biol Chem; 2014 Jul; 289(30):20526-42. PubMed ID: 24872420
[TBL] [Abstract][Full Text] [Related]
6. Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.
Devasundaram S; Rosati M; Valentin A; Weiss S; Itri V; Trinh HV; Bear J; Chowdhury B; LaBranche CC; Montefiori D; Ferrari G; Rao M; Kong XP; Zolla-Pazner S; Pavlakis GN; Felber BK
J Virol; 2020 Dec; 95(2):. PubMed ID: 33087466
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW
Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
[TBL] [Abstract][Full Text] [Related]
9. Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
Yu B; Morales JF; O'Rourke SM; Tatsuno GP; Berman PW
PLoS One; 2012; 7(8):e43903. PubMed ID: 22928048
[TBL] [Abstract][Full Text] [Related]
10. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
Doran RC; Tatsuno GP; O'Rourke SM; Yu B; Alexander DL; Mesa KA; Berman PW
PLoS One; 2018; 13(4):e0196370. PubMed ID: 29689099
[TBL] [Abstract][Full Text] [Related]
11. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
12. Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
Gilbert PB; Excler JL; Tomaras GD; Carpp LN; Haynes BF; Liao HX; Montefiori DC; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Kijak GH; Tovanabutra S; Francis DP; Lee C; Sinangil F; Berman PW; Premsri N; Kunasol P; O'Connell RJ; Michael NL; Robb ML; Morrow R; Corey L; Kim JH
PLoS One; 2017; 12(5):e0176428. PubMed ID: 28493891
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
14. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
16. Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice.
Wiehe K; Nicely NI; Lockwood B; Kuraoka M; Anasti K; Arora S; Bowman CM; Stolarchuk C; Parks R; Lloyd KE; Xia SM; Duffy R; Shen X; Kyratsous CA; Macdonald LE; Murphy AJ; Scearce RM; Moody MA; Alam SM; Verkoczy L; Tomaras GD; Kelsoe G; Haynes BF
J Immunol; 2017 Feb; 198(3):1047-1055. PubMed ID: 28011932
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.
Steers NJ; Ratto-Kim S; de Souza MS; Currier JR; Kim JH; Michael NL; Alving CR; Rao M
PLoS One; 2012; 7(8):e42579. PubMed ID: 22880042
[TBL] [Abstract][Full Text] [Related]
18. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
19. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
20. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
Tolbert WD; Van V; Sherburn R; Tuyishime M; Yan F; Nguyen DN; Stanfield-Oakley S; Easterhoff D; Bonsignori M; Haynes BF; Moody MA; Ray K; Ferrari G; Lewis GK; Pazgier M
mBio; 2020 Jun; 11(3):. PubMed ID: 32605979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
